MRI in children given gadodiamide injection: safety and efficacy in CNS and body indications

Eur J Radiol. 1996 Nov;23(3):190-6. doi: 10.1016/s0720-048x(96)01088-1.


The safety and efficacy of the MRI contrast medium gadodiamide injection (OMNISCAN) in children is summarised. Four open and three double-blind, multinational, multicentre comparative trials have been undertaken. Overall, 353 patients (15 days to 18 years, plus one 21 years) received gadodiamide injection, and 128 (2-18 years) received gadopentetate dimeglumine (Magnevist), intravenously at 0.1 mmol/kg body weight, to aid the identification of CNS and body lesions. Adverse events were reported in 13 (4%) patients given gadodiamide injection and 8 (6%) given gadopentetate dimeglumine; few patients reported injection-associated discomfort. The post-contrast scan gave more diagnostic information in 223 (63%) patients given gadodiamide injection (CNS and body indications). In the comparative trials, the post-contrast scan gave more diagnostic information for 91 (65%) and 82 (64%) patients given gadodiamide injection and gadopentetate dimeglumine, respectively (CNS indications only). Gadodiamide injection (0.1 mmol/kg body weight) was safe and effective in infants, children and adolescents.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • Adolescent
  • Central Nervous System Diseases / diagnosis*
  • Child
  • Child, Preschool
  • Clinical Trials, Phase III as Topic
  • Contrast Media*
  • Drug Combinations
  • Gadolinium DTPA
  • Gadolinium* / adverse effects
  • Humans
  • Infant
  • Infant, Newborn
  • Magnetic Resonance Imaging*
  • Meglumine / adverse effects
  • Multicenter Studies as Topic
  • Organometallic Compounds* / adverse effects
  • Pentetic Acid / adverse effects
  • Pentetic Acid / analogs & derivatives*
  • Randomized Controlled Trials as Topic
  • Safety


  • Contrast Media
  • Drug Combinations
  • Organometallic Compounds
  • Meglumine
  • Pentetic Acid
  • gadodiamide
  • Gadolinium
  • Gadolinium DTPA